Prevotella
bacterial vaginosis
mucin
sialidase
vaginal microbiome
Journal
Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876
Informations de publication
Date de publication:
03 Sep 2024
03 Sep 2024
Historique:
medline:
27
8
2024
pubmed:
26
8
2024
entrez:
26
8
2024
Statut:
ppublish
Résumé
Elevated bacterial sialidase activity in the female genital tract is strongly associated with poor health outcomes including preterm birth and bacterial vaginosis (BV). These negative effects may arise from sialidase-mediated degradation of the protective mucus layer in the cervicovaginal environment. Prior biochemical studies of vaginal bacterial sialidases have focused solely on the BV-associated organism
Identifiants
pubmed: 39186657
doi: 10.1073/pnas.2400341121
doi:
Substances chimiques
Neuraminidase
EC 3.2.1.18
Mucins
0
Bacterial Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2400341121Subventions
Organisme : Bill and Melinda Gates Foundation (GF)
ID : No. 270790 and INV-037720
Organisme : NSF | National Science Foundation Graduate Research Fellowship Program (GRFP)
ID : DGE 1745303
Organisme : Bill and Melinda Gates Foundation (GF)
ID : INV-048977 and OPP1189208
Déclaration de conflit d'intérêts
Competing interests statement:J.R. is a cofounder of LUCA Biologics, a biotechnology company focusing on translating microbiome research into live biotherapeutic drugs for women’s health. D.S.K. serves as equity holder of Day Zero Diagnostics.